header logo image


Page 455«..1020..454455456457..460470..»

OncoSec to Present at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020 – Yahoo Finance

August 12th, 2020 8:48 pm

SAN DIEGO and PENNINGTON, N.J., Aug. 10, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, President and Chief Executive Officer will present at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020.

The OncoSec presentation will begin at 12:30 PM ET and will available via webcast at https://wsw.com/webcast/btig/oncs/.

In addition, the Company will be available for virtual one-on-one meetings on August 10th and 11th. Interested parties should register for the conference via https://btig.meetmax.com/BTIGBiotech20.

About OncoSec Medical IncorporatedOncoSec Medical Incorporated is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead product candidate, TAVO, enables the intratumoral delivery of DNA-based interleukin-12 or IL-12, a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors. The company is currently evaluating TAVO in combination with the anti-PD-1 checkpoint inhibitor, KEYTRUDA (pembrolizumab), in two KEYNOTE clinical trials, including a pivotal trial in patients with anti-PD-1 checkpoint resistant metastatic melanoma and a phase 2 trial in metastatic triple negative breast cancer. OncoSec is also identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its novel Visceral Lesion Applicator designed to target deep internal lesions, such as liver, lung or pancreatic lesions. For more information, please visit http://www.oncosec.com.

TAVO is a trademark of OncoSec Medical Incorporated.

KEYTRUDAis a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Risk Factors and Forward-Looking StatementsThis release, as well as other information provided from time to time by the Company or its employees, may contain forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Forward-looking statements provide the Company's current beliefs, expectations and intentions regarding future events and involve risks, uncertainties (some of which are beyond the Company's control) and assumptions. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "should," "will" and "would" and similar expressions (including the negative of these terms). Although we believe that expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The Company intends these forward-looking statements to speak only at the time they are published on or as otherwise specified, and does not undertake to update or revise these statements as more information becomes available, except as required under federal securities laws and the rules and regulations of the Securities Exchange Commission ("SEC"). In particular, you should be aware that the success and timing of our clinical trials, including safety and efficacy of our product candidates, patient accrual, unexpected or expected safety events, the impact of COVID-19 on the supply of our candidates or the initiation or completion of clinical trials and the usability of data generated from our trials may differ and may not meet our estimated timelines. Please refer to the risk factors and other cautionary statements provided in the Company's Annual Report on Form 10-K for the fiscal year ended July 31, 2019 and subsequent periodic and current reports filed with the SEC (each of which can be found at the SEC's websitewww.sec.gov), as well as other factors described from time to time in the Company's filings with the SEC.

Story continues

Original post:
OncoSec to Present at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020 - Yahoo Finance

Read More...

Industrial Biotechnology Market Insights Business Opportunities, Current Trends And Restraints Forecast 2026 | Reports And Data – Levee Report

August 12th, 2020 8:48 pm

The Global Industrial Biotechnology Market Research Report methodically describes every component of the market and assists the reader in evaluating the current and future market trends and formulate business expansion strategies. The key growth trends and opportunities are offered through a comprehensive investigation and examination of the market. A detailed course of development is provided in the report, along with insights into businesses connected with it, which include firms, industries, organizations, vendors, and local manufacturers. Better products and services to gain global and regional market share form the competitive landscape of the industry.

The report is studied with reference to the current COVID-19 pandemic. The pandemic has impacted several segments of the market on both the global and regional levels. The market report comprises of extensive research done on the current and in the post-COVID-19 scenario for the market. The study covers the present and future impact of the COVID-19 crisis on the market.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1338

The report provides an in-depth analysis of the competitive landscape and covers profiles of key players, along with their product portfolios and business strategies.

Key players of the market mentioned in the report are:

BASF, Amyris, Borregaard, BioAmber, Codexis, Evolva, Fermentalg, Gevo, Global Bioenergies, Deinove, Metabolic Explorer, Novozymes, and Solazyme

The global Industrial Biotechnology market has been exponentially growing on a global scale. The upstream raw materials, increase in the population, expanding regions, demand and supply, and advancements in technologies have contributed to the increasing growth figures. Various analytical tools like SWOT analysis, Porters Five Forces analysis, and others are implemented in the study to provide a deeper analysis of the market and its competitive landscape. Furthermore, the report covers market history, changing scenarios, demand and supply, manufacturing, production and consumption ratio, and technological developments.

The report further studies the segmentation of the market based on product types offered in the market and their end-use/applications.

Type Outlook (Revenue, USD Million; 2016-2026)

Raw Material Outlook (Revenue, USD Million; 2016-2026)

Application Outlook (Revenue, USD Million; 2016-2026)

Request customization of the report @ https://www.reportsanddata.com/request-customization-form/1338

Regional bifurcation mentioned in the Industrial Biotechnology market report:

Focal Points of the Reports TOC:

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1338

Key objectives of the Industrial Biotechnology research report:

To get the Report Description and TOC, visit @ https://www.reportsanddata.com/report-detail/industrial-biotechnology-market

Thank you for reading our report. For more details on customization, please reach out to us. Our team will ensure the report is tailored as per your requirements.

David is an Experience Business writer who regularly contributes to the blog, He specializes in manufacturing news

Read the original:
Industrial Biotechnology Market Insights Business Opportunities, Current Trends And Restraints Forecast 2026 | Reports And Data - Levee Report

Read More...

Is Ligand Pharmaceuticals Inc. (LGND) the Top Pick in the Biotechnology Industry? – InvestorsObserver

August 12th, 2020 8:48 pm

Ligand Pharmaceuticals Inc. (LGND) is around the top of the Biotechnology industry according to InvestorsObserver. LGND received an overall rating of 77, which means that it scores higher than 77 percent of all stocks. Ligand Pharmaceuticals Inc. also achieved a score of 90 in the Biotechnology industry, putting it above 90 percent of Biotechnology stocks. Biotechnology is ranked 16 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Ligand Pharmaceuticals Inc. (LGND) stock is lower by -3.25% while the S&P 500 is up 1.19% as of 1:47 PM on Wednesday, Aug 12. LGND is down -$3.64 from the previous closing price of $111.90 on volume of 172,921 shares. Over the past year the S&P 500 has risen 15.28% while LGND is up 15.11%. LGND lost -$1.38 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Ligand Pharmaceuticals Inc. click here.

Read the rest here:
Is Ligand Pharmaceuticals Inc. (LGND) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Read More...

Is Avid Bioservices Inc (CDMO) a Winner in the Biotechnology Industry? – InvestorsObserver

August 12th, 2020 8:48 pm

Avid Bioservices Inc (CDMO) is near the top in its industry group according to InvestorsObserver. CDMO gets an overall rating of 68. That means it scores higher than 68 percent of stocks. Avid Bioservices Inc gets a 80 rank in the Biotechnology industry. Biotechnology is number 16 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 68 would rank higher than 68 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Avid Bioservices Inc (CDMO) stock is trading at $8.05 as of 2:32 PM on Wednesday, Aug 12, a gain of $0.35, or 4.55% from the previous closing price of $7.70. The stock has traded between $7.72 and $8.37 so far today. Volume today is 390,347 compared to average volume of 464,260.

To screen for more stocks like CDMO click here.

See more here:
Is Avid Bioservices Inc (CDMO) a Winner in the Biotechnology Industry? - InvestorsObserver

Read More...

Cellect Biotechnology Reports Second Quarter Financial and Operating Results; First Half 2020 Strategic Developments Create Long-Term Revenue…

August 12th, 2020 8:48 pm

TEL AVIV, Israel, Aug. 12, 2020 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today reported financial and operating results for the second quarter ended June 30, 2020. The Company's six-month progress includes the development of several strategic initiatives, including growth-oriented opportunities in pain management and COVID-19 related therapeutics.

"Despite the COVID-19 pandemic business disruptions and the near-term delays to completing and commencing our clinical programs in Israel and the U.S., respectively, we acted swiftly over the past few months to leverage our sought-after technology to create several long-term business initiatives to enhance our value," commented Dr. Shai Yarkoni, Chief Executive Officer. "In addition to pursuing a potential merger with a global leader in the high growth medical-grade cannabis market, which is being delayed due to COVID-19, we have either initiated or are contemplating other business development activities that will greatly benefit from our innovation, technology and know-how. I believe each of these opportunities represents meaningful catalysts for Cellect in multi-billion-dollar markets, subject to resolution of the COVID-19 pandemic and return to normal course of business."

Notwithstanding the continued delays due to COVID-19, the Company remains focused on the following operational and clinical objectives:

The Company's cash and cash equivalents totaled $7 million as of June 30, 2020, which includes the approximately $1.5 million (gross before expenses)resulting from several investors exercising certain warrants that were issued in February 2019.

SecondQuarter 2020 Financial Results:

*For the convenience of the reader, the amounts above have been translated from NIS into U.S. dollars, at the representative rate of exchange on June 30, 2020 (U.S. $1 = NIS 3.466).

About Cellect Biotechnology Ltd.

Cellect Biotechnology (APOP) has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of stem cell-based therapies.

The Company's technology is expected to provide researchers, clinical community and pharma companies with the tools to rapidly isolate stem cells in quantity and quality allowing stem cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company's current clinical trial is aimed at bone marrow transplantations in cancer treatment.

Forward Looking Statements

This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss Cellect's expectations regarding timing of the commencement of its planned U.S. clinical trial and its plan to reduce operating costs. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company's history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and clinical trial results; the Company's technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company's industry; unforeseen scientific difficulties may develop with the Company's technology; the Company's ability to retain or attract key employees whose knowledge is essential to the development of its products; and the Company's ability to pursue any strategic transaction or that any transaction, if pursued, will be completed. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, http://www.sec.gov, and in the Company's periodic filings with the SEC.

Cellect Biotechnology Ltd.

Consolidated Statement of Operation

Convenience

translation

Six months

ended

Six months ended

Three months ended

June 30,

June 30,

June 30,

2020

2020

2019

2020

2019

Unaudited

Unaudited

U.S. dollars

NIS

(In thousands, except share and per

share data)

Research and development expenses

837

2,901

7,086

1,364

3,564

General and administrative expenses

1,356

4,703

5,064

2,116

2,709

Operating loss

2,193

7,604

12,150

3,480

6,273

Financial expenses (income) due to warrants exercisable into shares

1,098

3,807

(7,111)

4,697

(5,919)

Other financial expenses (income), net

(15)

(55)

880

627

462

Total comprehensive loss

3,276

11,356

5,919

8,804

816

Loss per share:

Basic and diluted loss per share

0.010

0.034

0.029

0.024

0.004

Weighted average number of shares outstanding used to compute basic and diluted loss per share

338,182,275

338,182,275

200,942,871

365,428,101

224,087,799

Cellect Biotechnology Ltd.

Consolidated Balance Sheet Data

Convenience

translation

June 30,

June 30,

December 31,

2020

2020

2019

Unaudited

Unaudited

Audited

U.S. dollars

NIS

(In thousands, except share and per

share data)

CURRENT ASSETS:

Link:
Cellect Biotechnology Reports Second Quarter Financial and Operating Results; First Half 2020 Strategic Developments Create Long-Term Revenue...

Read More...

Where Does Beam Therapeutics Inc (BEAM) Stock Fall in the Biotechnology Field? – InvestorsObserver

August 12th, 2020 8:48 pm

The 47 rating InvestorsObserver gives to Beam Therapeutics Inc (BEAM) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 41 percent of stocks in the Biotechnology industry, BEAMs 47 overall rating means the stock scores better than 47 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 47 would rank higher than 47 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Beam Therapeutics Inc (BEAM) stock is down -6.18% while the S&P 500 is up 1.19% as of 2:33 PM on Wednesday, Aug 12. BEAM has fallen -$1.46 from the previous closing price of $23.62 on volume of 519,613 shares. Over the past year the S&P 500 is up 0.83% while BEAM is up 18.19%. BEAM lost -$2.68 per share the over the last 12 months.

To screen for more stocks like BEAM click here.

View original post here:
Where Does Beam Therapeutics Inc (BEAM) Stock Fall in the Biotechnology Field? - InvestorsObserver

Read More...

COVID-19 Impact on Biotechnology Market 2020 future development, manufacturers, trends, share, size and forecast edited by leading research firm -…

August 12th, 2020 8:48 pm

In the latest report, Report Ocean has provided unique insights about the Biotechnology Market. This report provides in detail analysis of market with revenue growth and upcoming trends. Biotechnology Market research report derived key statistics, based on the market status of the manufacturers and is a valuable source of guidance and direction for companies and individuals interested in Biotechnology Market.

This research report offers in-depth study about Market Size and Share, Product and Services, Company Profile, Regional Forecast, Consumer Preference, Market Competition, and Industry Chain Structure.

This research report represents the statistical data in the form of TABLES, CHARTS, and infographics to assess the market, its growth and development, and market trends of the Biotechnology Market during the forecasted period.

COVID 19 Impact on Biotechnology Market

The Coronavirus Pandemic (COVID-19) has affected every aspect of life worldwide. Under COVID-19 Outbreak, how the Biotechnology Market Industry will develop is also analyzed in detail in Chapter 1.7 of the report.

In Chapter 2.4, we analyzed industry trends in the context of COVID-19.

In Chapter 3.5, we analyzed the impact of COVID-19 on the product industry chain based on the upstream and downstream markets.

In Chapters 6 to 10 of the report, we analyze the impact of COVID-19 on various regions and major countries.

In chapter 13.5, the impact of COVID-19 on the future development of the industry is pointed out.

Request Free Sample Report athttps://www.reportocean.com/industry-verticals/sample-request?report_id=mai31385

competitive landscape:

Key players in the global Biotechnology market covered in Chapter 4:DanaherF. Hoffmann-La RocheThermo Fisher ScientificAgilent TechnologiesMerckQiagenIlluminaPerkinElmerAmgenBio-Rad LaboratoriesBioGen Medical InstrumentsAbbott Laboratories

This report also outlines the Major companies or players involved in the Biotechnology Market industry, along with product specifications, revenue generated, pricing strategies, contact information, information related to raw materials, equipment and demands. With the help of tables and figures, valuable insights on production, value, price, and gross margin of each player are offered.

Market Segmentation:

The segmentation study is considered as the key section to decide the target market with keen study of segments or smaller sections such as geographical regions, application and product type to optimize advertising technique and marketing strategies at regional as well as global level of the Biotechnology Market.

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2020-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:

North America (Covered in Chapter 6 and 13)

United States

Canada

Mexico

Europe (Covered in Chapter 7 and 13)

Germany

UK

France

Italy

Spain

Russia

Others

Asia-Pacific (Covered in Chapter 8 and 13)

China

Japan

South Korea

Australia

India

Southeast Asia

Others

Middle East and Africa (Covered in Chapter 9 and 13)

Saudi Arabia

UAE

Egypt

Nigeria

South Africa

Others

South America (Covered in Chapter 10 and 13)

Brazil

Argentina

Columbia

Chile

Others

Some of the Major Highlights of TOC covers:

Report Overview

Study Scope

Key Market Segments

Regulatory Scenario by Region/Country

Market Investment Scenario Strategic

Global Market Growth Trends

Industry Trends

SWOT Analysis

Porters Five Forces Analysis

Potential Market and Growth Potential Analysis

Industry News and Policies by Regions

Industry News

Industry Policies

Industry Trends Under COVID-19

Value Chain Biotechnology Market

Value Chain Status

Biotechnology Market Manufacturing Cost Structure Analysis

Production Process Analysis

Manufacturing Cost Structure of Biotechnology Market

Labor Cost of Biotechnology Market

Labor Cost of Biotechnology Market Under COVID-19

Sales and Marketing Model Analysis

Downstream Major Customer Analysis (by Region)

Value Chain Status Under COVID-19

Biotechnology Market Production, Revenue (Value), Price Trend by Type

Production and Market Share by Type

Revenue and Market Share by Type

Price by Type

Biotechnology Market Production, Consumption, Export, Import by Region

Production, Consumption, Export, Import by Region

Production, Consumption, Export, Import by Country

Production, Revenue, Price and Gross Margin

Industrial Chain, Sourcing Strategy and Downstream Buyers

Biotechnology Market Industrial Chain Analysis

Raw Materials Sources of Biotechnology Market major Players in 2019

Downstream Buyers

Biotechnology Market Forecast

Biotechnology Market Sales, Revenue and Growth Rate

Biotechnology Market Production, Consumption, Export and Import Forecast by Region

Biotechnology Market Production, Revenue and Price Forecast by Type

Biotechnology Market Consumption Forecast by Application

Biotechnology Market Forecast Under COVID-19

Years considered for this report:

Historical Years: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2020-2026

Inquire or Share Your Questions If Any before Purchasing This Report:https://www.reportocean.com/industry-verticals/sample-request?report_id=mai31385

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe, and Asia.

Link:
COVID-19 Impact on Biotechnology Market 2020 future development, manufacturers, trends, share, size and forecast edited by leading research firm -...

Read More...

Is Capricor Therapeutics Inc (CAPR) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

August 12th, 2020 8:48 pm

The 67 rating InvestorsObserver gives to Capricor Therapeutics Inc (CAPR) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 77 percent of stocks in the Biotechnology industry, CAPRs 67 overall rating means the stock scores better than 67 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Capricor Therapeutics Inc (CAPR) stock has fallen -12.65% while the S&P 500 is higher by 1.27% as of 11:28 AM on Wednesday, Aug 12. CAPR is lower by -$0.85 from the previous closing price of $6.72 on volume of 1,273,064 shares. Over the past year the S&P 500 is up 15.37% while CAPR is higher by 96.98%. CAPR lost -$1.66 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Go here to read the rest:
Is Capricor Therapeutics Inc (CAPR) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Read More...

Unity Biotechnology Inc. (UBX) market price of $11.78 offers the impression of an exciting value play – The InvestChronicle

August 12th, 2020 8:48 pm

At the end of the latest market close, Unity Biotechnology Inc. (UBX) was valued at $11.98. In that particular session, Stock kicked-off at the price of $12.20 while reaching the peak value of $12.29 and lowest value recorded on the day was $11.31. The stock current value is $11.78.

Recently in News on August 4, 2020, UNITY Biotechnology Announces $80M Debt Financing From Hercules Capital. UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that it has entered into a $80 million debt facility with Hercules Capital [NYSE: HTGC]. You can read further details here

Unity Biotechnology Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the companys stock is recorded $15.44 on 08/10/20, with the lowest value was $4.62 for the same time period, recorded on 03/13/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Unity Biotechnology Inc. shares are logging -23.70% during the 52-week period from high price, and 154.98% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $4.62 and $15.44.

The companys shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1416746 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Unity Biotechnology Inc. (UBX) recorded performance in the market was 63.38%, having the revenues showcasing 70.48% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 626.46M, as it employees total of 100 workers.

During the last month, 0 analysts gave the Unity Biotechnology Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 7.76, with a change in the price was noted +6.65. In a similar fashion, Unity Biotechnology Inc. posted a movement of +129.63% for the period of last 100 days, recording 418,635 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity The total Debt to Equity ratio for UBX is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of Unity Biotechnology Inc. in the period of last 50 days is set at 55.31%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 51.94%. In the last 20 days, the companys Stochastic %K was 63.33% and its Stochastic %D was recorded 74.31%.

If we look into the earlier routines of Unity Biotechnology Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 63.38%. Additionally, trading for the stock in the period of the last six months notably improved by 83.20%, alongside a boost of 76.35% for the period of the last 12 months. The shares increased approximately by 15.15% in the 7-day charts and went down by 59.40% in the period of the last 30 days. Common stock shares were driven by 70.48% during last recorded quarter.

Go here to read the rest:
Unity Biotechnology Inc. (UBX) market price of $11.78 offers the impression of an exciting value play - The InvestChronicle

Read More...

How Agriculture Biotechnology Market Will Dominate In Coming Years? Key Players: ADAMA Agricultural Solutions, Vilmorin, Bayer, Biocentury Transgene -…

August 12th, 2020 8:48 pm

Industry Overview of Agriculture Biotechnology Market Report 2020

Market Expertz has published yet another new report on the global Agriculture Biotechnology market. This report can help the user to better understand the opportunities and threats that are doled by the industry and its players. Additionally, this study is inclusive of the market scenario and factors like the players who influence and dominate the industry. The strategies of these players, the products they offer, their operating areas, and the opportunities are discussed in detail. The report serves the analysis of the global market share, segmentation, revenue growth estimation, and geographic regions of the market.

The report includes the latest coverage of the impact of COVID-19 on the Agriculture Biotechnology industry. The incidence has affected nearly every aspect of the business domain. This study evaluates the current scenario and predicts future outcomes of the pandemic on the global economy.

To request for a free sample of the insightful Agriculture Biotechnology market report click [emailprotected] https://www.marketexpertz.com/sample-enquiry-form/88805

This study analyses the growth of Agriculture Biotechnology based on the present, past and futuristic data and will render entire information about the Agriculture Biotechnology industry to the market-leading industry players that will guide the direction of the Agriculture Biotechnology market through the forecast period. All of these players are analyzed in detail to get details concerning their recent announcements and partnerships, product/services, investment strategies, and so on.

Competitive Landscape:

Agriculture Biotechnology market report highlights key players included in the market in order to render a comprehensive view of the competing players existing in the market. Company details, strategies, aptitude, history, cost analysis, and prevalent strategies

Leading Agriculture Biotechnology manufacturers/companies operating at both regional and global levels:

ADAMA Agricultural SolutionsVilmorinBayerBiocentury TransgeneCertisDow AgroSciencesEurofinsEvogeneGlobal Bio-chem TechnologySyngentaKWS SaatMarina BiotechMonsantoOthers

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

The Agriculture Biotechnology market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, markets and materials, CAPEX cycle, and the dynamic structure of the Agriculture Biotechnology market.

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted [emailprotected] https://www.marketexpertz.com/discount-enquiry-form/88805

Industry outlook:

Agriculture Biotechnology product types, applications, geographies, and end-user industries are the key market segments that are comprised in this study. The report speculates the prospective growth of the different market segments by studying the current market standing, performance, demand, production, sales, and growth prospects existing in the market.

The segmentation included in the report is beneficial for readers to capitalize on the selection of appropriate segments for the Agriculture Biotechnology sector and can help companies in deciphering the optimum business move to reach their desired business goals.

In market segmentation by types of Agriculture Biotechnology, the report covers-

BiochipsDeoxy ribonucleic acid (DNS) sequencingGenome editing toolsRibonucleic acid interference (RNAI)Synthetic biologyOthers

In market segmentation by applications of the Agriculture Biotechnology, the report covers the following uses-

Transgenic crops marketSynthetic biology-enabled products marketOthers

This Agriculture Biotechnology report umbrellas vital elements such as market trends, share, size, and aspects that facilitate the growth of the companies operating in the market to help readers implement profitable strategies to boost the growth of their business. This report also analyses the expansion, market size, key segments, market share, application, key drivers, and restraints.

Click here to inquire about customization and available discounts on the [emailprotected] https://www.marketexpertz.com/customization-form/88805

Highlights of the Agriculture Biotechnology market study:

Speculations for sales:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Agriculture Biotechnology market. Additionally, it includes a share of every segment of the Agriculture Biotechnology market, giving methodical information about types and applications of the market.

Key point summary of the Agriculture Biotechnology market report:

In the end, the Agriculture Biotechnology market is analyzed for revenue, sales, price, and gross margin.

Report customization:

Market Expertz also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Read the full Research Report along with a table of contents, facts and figures, charts, graphs, etc. @ https://www.marketexpertz.com/industry-overview/agriculture-biotechnology-market

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

About Us:Planning to invest in market intelligence products or offerings on the web? Then marketexpertz has just the thing for you reports from over 500 prominent publishers and updates on our collection daily to empower companies and individuals catch-up with the vital insights on industries operating across different geography, trends, share, size and growth rate. Theres more to what we offer to our customers. With marketexpertz you have the choice to tap into the specialized services without any additional charges.

Contact Us:John WatsonHead of Business Development40 Wall St. 28th floor New York CityNY 10005 United StatesDirect Line: +1-800-819-3052Visit our News Site: http://newssucceed.com

David is an Experience Business writer who regularly contributes to the blog, He specializes in manufacturing news

Original post:
How Agriculture Biotechnology Market Will Dominate In Coming Years? Key Players: ADAMA Agricultural Solutions, Vilmorin, Bayer, Biocentury Transgene -...

Read More...

Is Tauriga Sciences Inc (TAUG) The Right Choice in Biotechnology? – InvestorsObserver

August 12th, 2020 8:48 pm

The 29 rating InvestorsObserver gives to Tauriga Sciences Inc (TAUG) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 13 percent of stocks in the Biotechnology industry, TAUGs 29 overall rating means the stock scores better than 29 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 29 means the stock is more attractive than 29 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Tauriga Sciences Inc (TAUG) stock is unmoved 5.4% while the S&P 500 has risen 0.52% as of 2:42 PM on Tuesday, Aug 11. TAUG is flat $0.00 from the previous closing price of $0.03 on volume of 935,630 shares. Over the past year the S&P 500 has risen 17.16% while TAUG is flat 0.00%. TAUG lost -$0.04 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Tauriga Sciences Inc click here.

View post:
Is Tauriga Sciences Inc (TAUG) The Right Choice in Biotechnology? - InvestorsObserver

Read More...

Pharmaceuticals and Biotechnology R&D Market Growth, Statistics, By Application, Production, Revenue & Forecast To 2026 – Bulletin Line

August 12th, 2020 8:48 pm

It is our aim to provide our readers with report for Pharmaceuticals and Biotechnology R&D Market, which examines the industry during the period 2020 2026. One goal is to present deeper insight into this line of business in this document. The first part of the report focuses on providing the industry definition for the product or service under focus in the Pharmaceuticals and Biotechnology R&D Market report. Next, the document will study the factors responsible for hindering and enhancing growth in the industry. After covering various areas of interest in the industry, the report aims to provide how the Pharmaceuticals and Biotechnology R&D Market will grow during the forecast period.

The major vendors covered:

ROCHE, JOHNSON & JOHNSON, MERCK, NOVARTIS, PFIZER, SANOFI, BAYER, BRISTOL-MYERS SQUIBB, ASTRAZENECA, GLAXOSMITHKLINE, ABBVIE, ELI LILLY, BOEHRINGER SOHN, AMGEN, GILEAD SCIENCES, TAKEDA PHARMACEUTICAL, NOVO NORDISK, BIOGEN, ABBOTT, ASTELLAS PHARMA, TEVA PHARMACEUTICAL INDUSTRIES and more

The final report will add the analysis of the Impact of Covid-19 on Pharmaceuticals and Biotechnology R&D Market.

Request a sample copy @ https://www.reportsandmarkets.com/sample-request/global-pharmaceuticals-and-biotechnology-r-d-market-size-status-and-forecast-2020-2026?utm_source=bulletinline&utm_medium=38

The Pharmaceuticals and Biotechnology R&D Market report between the years 2020 2026 will highlight the current value of the industry. At the same time, there is also an estimate of how much this line of business will be worth at the end of the forecast period. As it is our goal to maintain high levels of accuracy at all times, we will take a look at the CAGR of the Pharmaceuticals and Biotechnology R&D Market. We make sure that all the information available in this report has excellent levels of readability. One way we achieve this target is by Pharmaceuticals and Biotechnology R&D Market segmentation. Going through the report for 2020 2026 will bring our readers up-to-date regarding this industry.

While examining the information from this document, one thing becomes clear, the elements which contribute to increase in demand for the product or service. At the same time, there will be a focus on what drives the popularity of these types of products or services. This report is for those who want to learn about Pharmaceuticals and Biotechnology R&D Market, along with its forecast for 2020 2026. Information regarding market revenue, competitive partners, and key players will also be available.

Segmentation

As discussed earlier, there is segmentation in the Pharmaceuticals and Biotechnology R&D Market report, to improve the accuracy and make it easier to collect data. The categories which are the dividing factors in the industry are distribution channels, application, and product or service type. With this level of segmentation, it becomes easier to analyze and understand the Pharmaceuticals and Biotechnology R&D Market. At the same time, there is emphasis on which type of consumers become the customers in this industry. When it comes to distribution channels, the Pharmaceuticals and Biotechnology R&D Market report looks at the different techniques of circulation of the product or service.

Regional Overview

In this part of the Pharmaceuticals and Biotechnology R&D Market report, we will be taking a look at the geographical areas and the role they play in contributing to the growth of this line of business. The areas of interest in this document are as follows Middle East and Africa, South and North America, Europe, and Asia Pacific. From the Pharmaceuticals and Biotechnology R&D Market report, it becomes clear which region is the largest contributor.

Latest Industry News

From this Pharmaceuticals and Biotechnology R&D Market report, the reader will also get to learn about the latest developments in the industry. The reason is that these products or services have the potential to disrupt this line of business. If there is information about company acquisitions or mergers, this information will also be available in this portion of the Pharmaceuticals and Biotechnology R&D Market report.

If you have any special requirements about this Pharmaceuticals and Biotechnology R&D Market report, please let us know and we can provide custom report.

Inquire more about this report @ https://www.reportsandmarkets.com/enquiry/global-pharmaceuticals-and-biotechnology-r-d-market-size-status-and-forecast-2020-2026?utm_source=bulletinline&utm_medium=38

About Us

ReportsAndMarkets.com allocates the globally available market research and many company reports from reputed market research companies that are a pioneer in their respective domains. We are completely an autonomous group and serve our clients by offering the trustworthy available research stuff, as we know this is an essential aspect of Market Research.

Contact Us

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Originally posted here:
Pharmaceuticals and Biotechnology R&D Market Growth, Statistics, By Application, Production, Revenue & Forecast To 2026 - Bulletin Line

Read More...

Is a Correction Looming Ahead? Vir Biotechnology, Inc. (VIR) – The News Heater

August 12th, 2020 8:48 pm

Vir Biotechnology, Inc. (NASDAQ:VIR) went down by -1.02% from its latest closing price when compared to the 1-year high value of $75.00 and move down -42.42%, while VIR stocks collected 4.07% of gains with the last five trading sessions. Press Release reported 8 hours ago that Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2020 Financial Results

Vir Biotechnology, Inc. (NASDAQ:VIR) 2 of the analysts out of 5 who provided ratings for Vir Biotechnology, Inc. stocks as a buy while 0 as overweight, 1 rated it as hold and 1 as sell. The average price we get from analysts is $32.50 which is -$17.99 below current price. VIR currently has a short float of 3.28% and public float of 106.55M with average trading volume of 1.47M shares.

VIR stocks went up by 4.07% for the week, with the monthly jump of 4.86% and a quarterly performance of 74.03%. The simple moving average for the period of the last 20 days is 5.77% for VIR stocks with the simple moving average of 82.96% for the last 200 days.

Many brokerage firms have already submitted their reports for VIR stocks, with JP Morgan repeating the rating for VIR shares by setting it to Underweight. The predicted price for VIR socks in the upcoming period according to JP Morgan is $26 based on the research report published on March 19, 2020.

Goldman, on the other hand, stated in their research note that they expect to see VIR stock at the price of $26. The rating they have provided for VIR stocks is Neutral according to the report published on March 13, 2020.

Robert W. Baird gave Underperform rating to VIR stocks, setting the target price at $17 in the report published on February 27, 2020.

After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, Vir Biotechnology, Inc. was unable to take a rebound, for now settling with -29.79% of loss for the given period.

The stock volatility was left at 6.16%, however, within the period of a single month, the volatility rate increased by 6.47%, while the shares surge at the distance of +6.21% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +48.97% upper at the present time.

In the course of the last 5 trading sessions, VIR went up by +4.07%, which changed the moving average for the period of 200 days to the total of +268.25% of gains for the stock in comparison to the 20-day moving average settled at $49.94. In addition, Vir Biotechnology, Inc. saw 318.77% in overturn over the period of a single year with a tendency to cut further gains.

Reports are indicating that there were more than several insider trading activities at Vir Biotechnology, Inc. (VIR), starting from Pang Phillip, who sold 12,500 shares at the price of $50.90 back on Aug 05. After this action, Rushing now owns 15,777 shares of Vir Biotechnology, Inc., valued at $636,222 with the latest closing price.

Pang Phillip, the Chief Medical Officer of Vir Biotechnology, Inc., sold 12,500 shares at the value of $50.90 during a trade that took place back on Aug 05, which means that Pang Phillip is holding 15,777 shares at the value of $636,222 based on the most recent closing price.

The current profitability levels are settled at -2144.35 for the present operating margin. The net margin for Vir Biotechnology, Inc. stands at -2158.98. Total capital return value is set at -62.52, while invested capital returns managed to touch -62.97.

Based on Vir Biotechnology, Inc. (VIR), the companys capital structure generated 0.27 points for debt to equity in total, while total debt to capital is set at the value of 0.27.

Read the original here:
Is a Correction Looming Ahead? Vir Biotechnology, Inc. (VIR) - The News Heater

Read More...

The Rejuvenation of PDS Biotechnology Corporation (NASDAQ:PDSB) – The Oracle Dispatch

August 12th, 2020 8:48 pm

The PDS Biotechnology Corporation (PDSB) shares are trading at lower $3.00 and the avg recommendation for the stock is Moderate Buy. while the current analyst price target stands at $6.48.

To add more color to this target, the companys high over the last year is $6.51 and the low is $0.62. Over the last 52 weeks, PDSB is down -53.92% while the S&P 500 is down -0.83%. The catalyst for this interesting swing was the companys recent earnings report.

A Notable Earnings Report

PDSB Return on Equity (ROE) is -105.10%, and its Return on Assets is -85.20%. All told, it is clear that, PDSB needs to be on your watchlist.

Find out when PDSB reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. PDSB has a short ratio of 0.37 and outstanding shares of 10.32M.

Company Outlook

PDSB has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 1.39 million and more growth is possible in the weeks ahead. Traders will also note the companys earnings per share came in at -3.02. PDS Biotechnology Corporation PDSB also noted assets of $23.93 million at the end of the last quarter. Investors should also keep an eye on sector updates as PDSB has historically followed its peers on positive news.

All told, PDS Biotechnology Corporation PDSB has strung together solid data and demonstrated underlying fundamentals. At its current valuation, PDSB represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.

PDS Biotechnology Corporation PDSB is now commanding a market cap of 45.33M and a float of 9.77M. PDSB is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of PDSB stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in PDSB, either long or short, and we have not been compensated for this article.

Post Views: 60

Read this article:
The Rejuvenation of PDS Biotechnology Corporation (NASDAQ:PDSB) - The Oracle Dispatch

Read More...

Next-Generation Biomanufacturing Market will touch a new level in upcoming year with Top Key Players like Applikon Biotechnology BV, bbi-biotech GmbH,…

August 12th, 2020 8:48 pm

Next-Generation Biomanufacturing Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis. It also provides market information in terms of development and its capacities.

Next-Generation Biomanufacturing Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Get Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=280469

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in This Report:

Applikon Biotechnology BV, bbi-biotech GmbH, Danaher Corporation, Eppendorf AG, Esco Group of Companies, GEA Group Aktiengesellschaft, Meissner Filtration Products, Inc., Merck KGaA, PBS Biotech, Inc., Pierre Gurin, Sartorius AG, Shanghai Bailun Biotechnology Co. Ltd., Solaris Biotechnology Srl., Thermo Fisher Scientific Inc., ZETA GmbH

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Next-Generation Biomanufacturing market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Next-Generation Biomanufacturing markets trajectory between forecast periods.

Buy Exclusive Report with Attractive Discount @:

https://www.a2zmarketresearch.com/discount?reportId=280469

Reasons for buying this report:

Table of Contents

Global Next-Generation Biomanufacturing Market Research Report 2020 2026

Chapter 1 Next-Generation Biomanufacturing Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Next-Generation Biomanufacturing Market Forecast

If You Have Any Query, Ask Our Experts:

https://www.a2zmarketresearch.com/enquiry?reportId=280469

If you have any special requirements, please let us know and we will offer you the report as you want.

Link:
Next-Generation Biomanufacturing Market will touch a new level in upcoming year with Top Key Players like Applikon Biotechnology BV, bbi-biotech GmbH,...

Read More...

COVID-19: Investigations in the Time of Coronavirus: Conducting FCPA Investigations during the Pandemic | Latin America – ICLG.com

August 12th, 2020 8:47 pm

Latin America has been especially hard hit in recent months by the ongoing COVID-19 pandemic, as describe...

Latin America has been especially hard hit in recent months by the ongoing COVID-19 pandemic, as described in WilmerHales recent client alerthere. The resulting travel restrictions, physical safety precautions and public health concerns have created uncertainty for many companies confronting the need to conduct cross-border Foreign Corrupt Practices Act (FCPA) investigations in the region, where some countries are currently difficultor impossibleto access.[1]

Despite these challenges, effective internal investigations remain central to a robust FCPA compliance program, as underscored by the recently released FCPA2020 Resource Guide, summarized by WilmerHalehere. The Department of Justice (DOJ) has announced that it does not expect any slowdown in its FCPA enforcement actions during the pandemic.[2]Moreover, the goals of an internal investigation go beyond satisfying the requirements of government authorities. Conducting a thorough, reliable and effective FCPA investigation is in the best business interests of the company itself.

With this difficult environment in mind, this client alert sets out 10 key tips for conducting effective Latin America-focused FCPA investigations under pandemic conditions.

The first step in any internal investigation is important: frame the investigation. Ask the following questions, which can be especially important and complex during the pandemic:[3]

In any Latin American FCPA investigation, having a well-organized team in place is criticaleven more so during the current crisis. While the pandemic restricts travel, an investigation may rely even more heavily on local resources to stand up, carry out and manage the investigation.[4]

A combination of local and international expertise is essential. Be sure to consider the language skills of these team members and to structure any engagement so that their work enjoys applicable attorney-client privilege and/or work product privilege protections. The team should include:

A crucial consideration for assembling a team is understanding how legal privilege will apply. Failing to understand how privilege appliesor doesntin the country where the investigation is taking place can be a major and potentially fatal pitfall. Because many Latin American countries are civil law jurisdictions, their legal privilege protections operate in a manner fundamentally different from those familiar to US lawyers.[5]

For example, only in fall 2019 did Mexicos antitrust authority, the Federal Economic Competition Commission (COFECE, as abbreviated in Spanish), issue guidelines for recognizing attorney-client communication protections in connection with antitrust investigations.[6]Although Mexican law does generally prohibit the disclosure of client information, it does not include broad legal protection from government seizure. This risks sensitive disclosure to government authorities if not handled correctly. Recent case law suggests that these protections may be expanding, but the current legal landscape presents more questions than answers.[7]

Companies should be vigilant in maintaining and protecting privileged material during the course of a Latin America FCPA investigation. This may prove even more important during the pandemic, when coordinating is more likely to be done via email, text and other written meansmeans that government authorities may try to collect and over which companies may not have as much control as in non-pandemic conditions.

Even prior to the pandemic, preserving, archiving and collecting local documents and evidence for investigations in Latin America could prove challenging. Today, in the midst of COVID-19, those challenges have multiplied. Working swiftly and coordinating with the on-the-ground team will be critically important.

Prompt document preservation is the most important first step to ensure a complete investigation. Of course, relying on individuals themselves for preservation and collection while working remotely raises its own issues. When planning out the document preservation and collection process, consider how to stage processes and requests to minimize the possibility of spoliation. A truly bad actor may be willing to destroy evidence at the first sign of an investigation, so to the extent practical, IT should take steps to preserve evidence (such as by remote back up and capture of data) before preservation notices are sent.

Once those key preservation steps have been taken, another important step is sending a preservation notice to individuals who are likely to have relevant evidence. The preservation notice directs these individuals not to delete or destroy material relevant to the investigation.[8]In Latin America, even in companies where employees are expected to have a working knowledge of English, providing translations of this noticein Spanish, Portuguese and/or any other relevant languageswill be critical to ensuring compliance. In addition, employees who receive a preservation notice should be required to acknowledge receipt via email or other written means, and IT experts should track this acknowledgment information.[9]

The pandemic will likely also make traditional in-person collection efforts difficult if not impossible to complete, so creativity will be required. Obviously, where employees cell phones or laptops can be imaged remotely, such imaging is a key first step. In addition, identifying and collecting text messages, chats and conversations through applications such as WhatsApp (widely used for business in Latin America) is essential.[10]You may also consider collecting from personal accounts or personal devices, especially if individuals indicate that they used personal accounts for business-related communications and data storagewhich is likely happening more often with people working more from home. But when doing so, pay particular attention to the limits local privacy law and regulation may place on those efforts, as discussed next.

The process of preserving and collecting relevant data and documents is made more complex by Latin Americas patchwork of data privacy protections, which can complicate even the most straightforward FCPA investigation. This is especially true if an investigation might attract the interest of enforcement authorities in the United States or Europe. Add to this the specific challenges presented by the pandemic, and the risks can seem dizzying. Local counsel or US counsel with links to trusted local practitioners will be invaluable in navigating Latin Americas complex and ever-changing data privacy regimes.

Many Latin American countries have been heavily influenced by the European Unions General Data Protection Regulation. But countries in the region also have adopted a special emphasis on consent for processing data and for legitimizing transfers to inadequate countries (though it is rarely clear which outside countries are deemed adequate).[11]Each country also presents unique data protection rules and investigation challenges, which require country-specific legal analysis. For more discussion on privacy laws in Latin America, see WilmerHales detailed analysishere.

Not surprisingly, the pandemic itself now shapes and tests the regions maintenance of these privacy rules. In Brazil and Panama, for example, the implementation of recently enacted privacy laws will likely be postponed in response to the pandemic.[12]On the other hand, COVID-19 and the response to it have complicated some of the commonly used approaches to comply with foreign data privacy laws. In some cases, investigation teams have deployed US counsel to review data within the jurisdiction; that is difficult now, if not impossible, in many jurisdictions due to travel restrictions.

With this complicated and ever-changing set of data privacy protections across Latin Americamany of which are not intuitive to counsel trained in the United States, Europe or elsewherecompanies conducting FCPA investigations in Latin America should engage local experts to ensure that an investigation does not run afoul of local data privacy laws.

In addition, local labor and employment law may impact when, how and whether employee interviews may take place in an FCPA investigation as well as what the scope of permissible employee discipline may be. A discussion of employment law across Latin America is beyond the scope of this alert. The complexity of local employment law, like privacy law, underscores the importance of considering at the outset of an FCPA investigation whether and how to engage experienced local counsel in the jurisdiction at issue.[13]

As WilmerHale described in its2019 FCPA Year in Review, local enforcement authorities in Latin America have continued recently to investigate alleged corruption within their borderswith or without US authorities cooperation.

For example, Brazils President Jair Bolsonaro initiated his administration in January 2019 with a promise to stamp out corruption in Brazil. President Bolsonaro has introduced broad anti-corruption legislation[14]and Brazilian prosecutors have been active over the past few years in tackling deep-rooted corruption in the country. However, the pandemicand the Bolsonaro administrations own corruption scandalspresent fundamental challenges to these goals, including the Brazilian governments diversion of resources that had been dedicated to investigating and prosecuting COVID-19-related corruption.[15]

In Mexico, President Andrs Manuel Lpez Obrador also campaigned on an anti-corruption platform and took actions at the outset of his administration to combat graft. For example, his administration has gone after the countrys national oil company, Pemex, including charging and even arresting former Pemex executives living abroad.[16]In 2019, President Obrador appointed the countrys first chief anticorruption prosecutor, Luz Mijangos Borja, who was reported to have initiated 680 investigative cases in the first eight months of her term.[17]

Given this and similar recent investigation activity,[18]local enforcement interests have always been an important consideration in FCPA investigations. But during the pandemic, local authorities enjoy greater access to documents and individuals on the ground than do US officials. The importance of expecting and planning for potential local investigations is only heightened as a result.

Communication with relevant outside stakeholders in an FCPA investigation, including, where relevant, enforcement authorities and external auditors, has always been critically important.

The pandemic has only underscored this need for communicationDOJ and Securities and Exchange Commission (SEC) officials have recently highlighted the importance of communicating COVID-19 challenges to enforcement authorities, and they have signaled that these agencies will work with companies to address investigatory issues presented by the pandemic. For example, in April, officials from the DOJ and SEC FCPA units explained that they are trying very hard to be sensitive to the realities of what everybody is dealing with.[19]A few weeks thereafter, in mid-May, DOJ and SEC officials shared that their foreign bribery units were experiencing pandemic-related challenges but were in no way hitting the pause button on their investigations.[20]

Similar considerations also apply to communicating with external auditors. In certain instances, a company may be required to inform its regular outside auditor of an FCPA investigation.[21]In those cases, pandemic-related challenges that affect the inquirys timing, scope and action plan should be communicated to external auditors sooner rather than later.

Although the pandemic presents challenges to Latin America FCPA investigations for companies and regulators alike, it has also presented opportunities to take advantage of new technologies and creative strategies. For example, firms might cut significant costs by standing up remote document review platforms via remote secure workspacesof course, ensuring compliance with local privacy laws.[22]For further discussion of such technology and strategies in the investigations and strategic response context, see WilmerHales analysishere. (WilmerHale also releases CLE credit webinars about cutting-edge investigation strategies during COVID-19, ashere, so please feel free to subscribe to the latest news and events from the firm.)

In the current environment, conducting interviews virtually where possible under local law and investigation circumstances has become a common approach.[23]Video interviews, of course, pose their own challenges and limitations. It is important to be realistic about how long participants can be engaged during a videoconference;[24]it may be better to break interviews into two half-day sessions rather than one full day. Finally, in the interest of maintaining the confidentiality of the investigation, counsel should attempt to avoid sending documents to the intervieweeparticularly one who is not employed by the client or its subsidiarybut rather should try to share documents on screen during the interview, in real time.

When relying on new technologies, hope for the best but plan for the worst. For example, if you are conducting a videoconference, have a backup telephone line. If conducting remote document review, make sure to build in time for technical difficulties and system shutdowns.

Finally, the most important tip for conducting an FCPA investigation in Latin America during the pandemic:be flexible. Companies, individuals and regulators are all working to continue their lives and livelihoods during this global health emergency. Even the most seasoned investigators should be prepared for both the challenges and the opportunities presented by the pandemic, as outlined in each of the tips above.

WilmerHale, too, remains abreast of the latest developments in FCPA enforcement, Latin America COVID-19 response (for example, see WilmerHales latest client alert onCOVID-19 response in Latin America) and other legal issues around the globe. We are available to provide timely guidance for our clients and partners.

WilmerHale has strong relationships with a wide range of local consultants and local counsel throughout Latin America. In certain countries, we have connections with multiple firms that might be considered collaborative partners, depending on the nature of the matter. The firm also taps its alumni network where useful in pursuit of our clients legal and business objectives. These resourcesemployed in concert with WilmerHales FCPA investigation expertisehave helped countless firms navigate complicated and high-stakes issues in cross-border investigation and litigation, including some of the most common complications discussed in this alert.

[1] Since March 31, 2020, the US State Department has issued a global level four do not travel health advisory, encouraging US citizens to avoid all international travel due to the global impact of COVID-19. Furthermore, some Latin American countries, such asArgentina,Bolivia,Chile,Colombia,Costa Rica,El Salvador,Guatemala,PanamaandParaguayhave effectively closed their borders to non-citizens and non-residents.Ecuadoris imposing a mandatory 14-day preventative quarantine on all non-citizens and non-residents in government-approved temporary housing or hotels. Some countries, such asBrazil,Mexicoand theDominican Republic, still have at least somewhat open borders. However, Mexico has announced that it allows only essential travel of non-citizens and non-residents from the United States, and some travelers may be asked to provide an employer letter certifying the essential nature of their business at hotels.Seehttps://mx.usembassy.gov/travel-restrictions-fact-sheet/.

[2] At a virtual FCPA conference on July 14, DOJ Criminal Division Chief Brian Rabbit stated that he expects to see a number of FCPA settlements this year: 2020 has obviously been challenging in a number of different ways, but we have been able to move forward with a number of key prosecutions and resolve a number of cases in 2020, including the Novartis case. I expect to see more of those in the coming months additional FCPA resolutions despite the pandemic, so that obviously remains a priority.https://globalinvestigationsreview.com/article/jac/1228948/acting-criminal-division-chief-expects-more-fcpa-resolutions-in-coming-months.

[3]https://www.wilmerhale.com/en/insights/publications/united-states-handling-internal-investigations.

[4]https://www.wilmerhale.com/en/insights/publications/2016-11-22-united-states-handling-internal-investigations;https://www.wilmerhale.com/en/insights/publications/20171220-beginning-an-internal-investigation-the-uk-perspective.

[5]https://www.americanbar.org/groups/business_law/publications/blt/2016/07/12_borrasso/.

[6]https://www.cofece.mx/wp-content/uploads/2019/09/DOF-30septiembre2019-01.pdf;https://www.justice.gov/opa/pr/antitrust-division-applauds-recognition-attorney-client-privilege-mexicos-competition-agency.

[7]https://globalcompetitionreview.com/article/1209247/mexico-recognises-legal-privilege-in-antitrust-probes

[8]https://www.wilmerhale.com/en/insights/publications/united-states-handling-internal-investigations.

[9]https://www.wilmerhale.com/en/insights/publications/united-states-handling-internal-investigations.

[10]https://www.wilmerhale.com/en/insights/publications/united-states-handling-internal-investigations.

[11]https://www.wilmerhale.com/en/insights/media/recording---wilmerhale-webinar-emerging-privacy-and-cybersecurity-laws-in-latin-america-and-asia.Unless otherwise indicated, all references in this section come from this WilmerHale webinar.

[12] For example, last year, Panama enacted a data protection law that was scheduled to enter into force in March 2021; only time will tell whether the pandemic slows the implementation or enforcement of this regulation.Seehttps://www.lexology.com/library/detail.aspx?g=58c7fd6b-d468-40fb-b330-83c4d9387585. And in Brazil, lawmakers recently voted to postpone the deadline for compliance with the General Data Protection Law from August 2020 to January 2021, citing concerns about the economic impacts of the pandemic (seehttps://www.wilsoncenter.org/blog-post/impact-postponing-brazils-data-protection-law;https://economia.estadao.com.br/noticias/geral,senado-aprova-projeto-que-suspende-prazos-contratuais-ate-outubro-aluguel-residencial-fica-de-fora,70003259159).

[13] See, e.g.,https://globalinvestigationsreview.com/chapter/1179068/beginning-an-internal-investigation-the-uk-perspective, 5.3.2.

[14]https://www.wilmerhale.com/en/insights/client-alerts/20200228-latin-america-anti-bribery-year-in-review-2019-developments-and-predictions-for-2020

[15]https://www.cnn.com/2020/07/08/americas/brazil-coronavirus-corruption-intl/index.html;https://www.ft.com/content/94c87005-7eb1-47c4-9698-5afb2b12ab54;https://riotimesonline.com/brazil-news/brazil/politics-brazil/investigations-on-covid-19-related-corruption-amount-to-r1-07-billion/.

[16]https://www.wilmerhale.com/en/insights/client-alerts/20200228-latin-america-anti-bribery-year-in-review-2019-developments-and-predictions-for-2020

[17]https://fcpablog.com/2019/12/18/new-corruption-prosecutor-opens-680-investigations/.

[18] Other Latin American enforcement authorities that have shown recent interest in dedicating significant resources to corruption investigations include Ecuador, in the case of PetroEcuador, for example, and Venezuela, in the case of PDVSA, for example.WilmerHale, Foreign Corrupt Practices Act Alert: Global Anti-Bribery Year-in-Review: 2018 Developments and Predictions for 2019(Jan. 17. 2019),https://www.wilmerhale.com/en/insights/client-alerts/20190117-global-anti-bribery-year-in-review-2018-developments-and-predictions-for-2019.

[19]https://globalinvestigationsreview.com/article/jac/1226073/fcpa-officials-urge-companies-to-communicate-pandemic-related-difficulties-quickly.

[20]https://globalinvestigationsreview.com/article/jac/1226760/sec-enforcement-chief-discusses-coronavirus-challenges;https://globalinvestigationsreview.com/article/jac/1227005/were-not-hitting-the-pause-button--says-sec-foreign-bribery-chief.

[21]https://www.sec.gov/spotlight/fcpa/fcpa-resource-guide.pdf.

[22]https://www.wilmerhale.com/en/insights/client-alerts/20200409-government-investigations-and-covid-19-remain-engaged-and-prepare-for-a-post-crisis-response.

[23]https://www.wilmerhale.com/en/insights/client-alerts/20200409-government-investigations-and-covid-19-remain-engaged-and-prepare-for-a-post-crisis-response.

[24]https://www.wsj.com/articles/why-does-zoom-exhaust-you-science-has-an-answer-11590600269.

This article was first published here.

Read this article:
COVID-19: Investigations in the Time of Coronavirus: Conducting FCPA Investigations during the Pandemic | Latin America - ICLG.com

Read More...

How Close Are We To Making Babies from Bone Marrow? – Discover Magazine

August 12th, 2020 8:45 pm

In 2007, a group of researchers reported a startling discovery: They had created sperm-like cells out of stem cells taken from the bone marrow of human men. Two years later, however, the study was retracted due to charges of plagiarism. Thirteen years later, the ability to create functional human sperm out of stem cells remains elusive.

Scientists have been trying to figure out how to create functioning human gametes eggs and sperm from stem cells for 20 or 30 years, says Vittorio Sebastiano, a stem cell biologist at Stanford University whose research focuses on reproductive biology. Doing so would help people struggling with infertility have children and help scientists unlock the secrets of human development. Since 2007, scientists have made considerable progress on this front, creating healthy mouse pups from stem cell-generated gametes and even immature human egg cells. But there is still a long road ahead before scientists will be able to convert skin or bone marrow into babies.

We are trying to really find ways to efficiently, robustly generate germ cells that can be, in the short term, used to understand the biology of these concepts, but in the long term [used to be] able to restore fertility, says Sebastiano.

When the first baby conceived via in vitro fertilization (IVF) was born in 1978, it was a major step forward for reproductive science and a precursor to the stem cell research conducted by Sebastiano and others today, he says. But IVF is not an option for every individual or couple trying to have a biological child, including those who are born without gametes or who receive aggressive cancer treatments at a young age. This scientific technique would offer these individuals a new shot at reproduction.

The next major step came in the 2000s, with the creation of induced pluripotent stem cells (iPSCs). These cells are taken from blood or skin cells and reprogrammed to behave like embryonic cells, which have the ability to develop into any type of cell in the body. Since then, researchers have been trying to figure out how to turn these embryonic-like cells into functional sperm and eggs.

A colony of induced pluripotent stem cells used to treat the rare genetic disorder Fanconi anemia. (Credit: Juan Carlos Izpisua Belmonte, Salk Institute for Biological Studies)

Part of what has made this work so challenging is that scientists havent been able to fully grasp what happens in a human embryo during normal development, says Sebastiano. Scientists understand this process in mice because the rodents are easy to study in the lab. But ethical restrictions and technical factors (like having access to the embryos at just the right point in time) make this phenomenon hard to study in people, he says.

Despite the roadblocks, scientists have made significant progress in the last 10 years. In 2012, a group of researchers in Japan created fertile mouse eggs from iPSCs and used those eggs to breed healthy mouse pups. In [the] mouse, the whole circle has already been completed, says Sebastiano. Now it has been shown by a couple of groups in the UK and in Japan that you can generate embryonic-like cells from mice and then you can actually push these cells to become eggs or sperm, fully functional.

In 2018, the same group of Japanese scientists made another major breakthrough. Using human blood cells and the pluripotent stem cell technique, they managed to produce immature human eggs.

Similar efforts to create sperm are not as far along, says Sebastiano. Several efforts over the years have purported to create sperm-like cells, including the 2007 blood marrow study. A much-heralded study published in 2014 also made major news, but Sebastiano says the development of the cells in that study didnt go far beyond the earliest stages of differentiation.

But, we are actively working on it, says Sebastiano. Probably in the next few years we will be able to generate fully functional sperm and fully functional oocytes. Then, the question will be how do scientists test the quality of these gametes, he says.

The only way to fully assess the quality and functionality of a sperm or egg is to use it to, well, try to fertilize another gamete and produce a baby. Thats why this work has to be approached with the utmost care, says Sebastiano. He hypothesizes that once scientists have developed techniques that they think produce mature human oocytes and sperm, the next step will be testing these techniques in primates. That way, researchers can follow the entire life of individual animals produced from this technique to see if any unexpected problems develop, he says.

Sebastiano has no doubt that one day, these stem cells could help individuals struggling with infertility to produce healthy children. This, along with a fascination with biological development, is what drives Sebastianos work. There are also, of course, significant ethical considerations that have to be carefully considered. This technique has the potential to affect human life on a generational level, he notes. And many people also raise concerns about other future consequences, like the ability to create designer babies or produce offspring from hairs stolen from unsuspecting celebrities. Bioethics experts have written about the need to start working through the medical and legal issues around this technique now, before it is viable.

There is a need actually to develop this, but since we are really dealing with a very unique cell type we need to be cautious, says Sebastiano.

Go here to read the rest:
How Close Are We To Making Babies from Bone Marrow? - Discover Magazine

Read More...

This common eye issue might be a sign of coronavirus infection – BGR

August 12th, 2020 8:44 pm

The clinical presentation of COVID-19 can include a variety of symptoms, but not all patients exhibit the same signs, and many infected people are asymptomatic. The novel coronavirus doesnt even have that many specific signs that would allow physicians to diagnose the infectious disease without a PCR test. The sudden loss of smell and taste is one such unique symptom thats likely to appear after a COVID-19 infection. But not for everyone.

Thats not the only downside of these unspecific COVID-19 symptoms. You might freak out whenever you experience a potential COVID-19 symptom, as youll have no way of knowing whether its the virus or something else. Only a test can bring you peace of mind, because the virus can infect various parts of the body, not just the lungs. The eye is one location where the virus can multiply, giving you a red eye or pink eye condition that you wouldnt necessarily associate with COVID-19. However, you should absolutely be aware of this possibility, as this manifestation of COVID-19 could be serious, and could even impact your eyesight.

A nurse in Kirkland, Washington said back in late March that every patient shed seen after testing positive for coronavirus had red eyes. They called the phenomenon allergy eyes because allergies can give you the same condition. Other healthcare workers noticed the same symptom in Canada in early March, detailing a case of keratoconjunctivitis in a 29-year-old patient who experienced no other major signs of COVID-19 infection. The study was published in The Canadian Journal of Ophthalmology.

The young woman spent a month in the Philippines and one day in San Francisco before returning to Canada. After one day of experiencing conjunctivitis, a clear watery discharge, and photophobia in her right eye, she went to an eye doctor. Other symptoms included rhinorrhea, cough, and nasal congestion, which we now know can be caused by COVID-19. She did not have a fever, but the medication she took over the counter may have masked it.

She returned on February 29th and went to the hospital multiple times in early March with worsening eye-related symptoms. She was diagnosed with keratoconjunctivitis, which is a complex eye condition.

The anatomy of the human eye. Image source: macrovector/Adobe

As the name suggests, the diagnosis is comprised of two distinct elements. Keratitis is the inflammation of the cornea or the transparent part of the eye in front of the pupil and the iris. Conjunctivitis, meanwhile, is the inflammation of the transparent tissue that covers the white of the eye and the surface of the eyelid. In either case, you might refer to it as a red eye or pink eye the illustration above shows the anatomy of the eye.

Now, heres an image of the patients eye taken before her second visit dated March 5th:

From the study: External photograph of the right eye taken by the patient before the second visit (March 5th) to the eye clinic demonstrating marked conjunctival injection and watery discharge. Photograph provided by the patient (used with permission). Image source: The Canadian Journal of Ophthalmology

Her eyesight was not impaired after the first two visits, but on March 5th, her vision had started to decline from 20/20 visual acuity to 20/40 pinhole to 20/30. Further examinations revealed epithelial damage and the patient continued the prescribed treatment for her condition. She did not qualify for COVID-19 testing according to the Canadian protocols at the time, but doctors had collected eye swabs to test for chlamydia, gonorrhea, and bacterial culture. The tests were negative, but the tests were later used to check for the presence of SARS-CoV-2 in the eye.

By March 6th, COVID-19 testing in Canada had changed, and she qualified for testing. A PCR test on March 8th was positive, and then samples from her eye were tested as well, confirming that the virus was present for the lesions in the eyes.

From the study: Schematic representation of the slit-lamp examination findings over progressive clinic visits; note the increase in the cornea lesions over time. Image source: The Canadian Journal of Ophthalmology

To the best of our knowledge, this is the first reported case of COVID-19 (caused by the SARS-CoV-2 virus) presenting with keratoconjunctivitis as the main symptom, the researchers concluded.

The patient did not present with conjunctivitis as previously reported for COVID-19 cases, but as keratoconjunctivitis. It was also apparent from the clinical examinations that the epithelial defects varied from one examination to the next and appeared as a pseudodendrite perhaps from a healing epithelial defect or possibly as a progressing subepithelial infiltrate.

The patients primary symptom and reason for repeatedly seeking care was a red eye with watery discharge, the study reads. If youre experiencing similar eye issues, you should consider the possibility of being infected with SARS-CoV-2. The CDC has a thorough list of coronavirus symptoms that you should check out if you suspect an infection. The New York Times created an interactive infographic that shows the most common symptoms associated with the illness.

The researches warn that healthcare workers treating patients that manifest such symptoms should know that a red eye could be an indication of COVID-19. Patients who have a red eye; respiratory symptoms such as cough and shortness of breath; and recently traveled to areas with known outbreaks are at higher risk of having COVID-19, the doctors note. Clinical interactions with any patients presenting with similar upper respiratory tract symptoms should be done with mouth and eye protection routinely if exposure to the patients secretions is possible. n this particular case, five physicians and three healthcare workers had to be placed in self-isolation for 14 days after treating the woman.

Chris Smith started writing about gadgets as a hobby, and before he knew it he was sharing his views on tech stuff with readers around the world. Whenever he's not writing about gadgets he miserably fails to stay away from them, although he desperately tries. But that's not necessarily a bad thing.

Read the original here:
This common eye issue might be a sign of coronavirus infection - BGR

Read More...

How to lower your risk of vision loss – Midhurst and Petworth Observer

August 12th, 2020 8:44 pm

Eyesight deterioration and general eye health: what can I do to protect my vision?

It is easy to take your eyes and sight for granted, but if you develop problems, you will soon realise how much you depend on your vision every moment of every single day.

That is why it is important to look after your vision now before issues might arise that could have been avoided. The good news is that there are things you can do to lower your risk of vision loss. Lets take a look at some of them.

Investigate your familys healthy history

It is important to learn more about the health history of your family. This way, you can know if you are at a higher risk of any eye disease. For example, check if any of your family has glaucoma, high blood pressure or diabetes. If they do, you should make your eye doctor aware of this so that your eyesight can be monitored.

Regular screening for conditions like glaucoma can spot the problem early and provide you with support. Conditions like diabetes and high blood pressure can lead to eye problems if they are not addressed.

Thankfully, there is a lot of research and new treatment developments, such as at the Tej Kohli Cornea Institute, that are going to help with eye conditions.

Everyone is always telling you to enjoy a healthy diet. In particular, this is going to be important for preventing vision loss. For example, you should make sure that you enjoy a lot of fruit and vegetables in your diet. Studies are showing that leafy vegetables contain nitrates, which can lower your risk of glaucoma by up to 30 percent. This works by improving blood flow to your eyes through the nitric oxide that is created.

Making a conscious effort to adjust your meals and snacks during the day can really make a difference.

In recent years, the damage of smoking has been recognised across the world. But did you know that smoking doesn't just affect your lungs? It can also cause damage to your eyes too. For example, you can be more at risk of macular degeneration and glaucoma. It is time to kick the habit and focus on living a healthier lifestyle. While this can be difficult at first, there are many advantages to giving up smoking. Do not be afraid to reach out for support.

There are a lot of things in your daily life that can increase the risk of eye damage. You should always wear protective eyewear if you work in construction or other jobs where there are machinery and chemicals. In addition, everyone is advised to wear sunglasses in order to block out harmful UV light.

Even if you go swimming, it is recommended that you wear goggles so that chlorine does not irritate your eyes. Simple steps like these ensure your vision is protected.

Continued here:
How to lower your risk of vision loss - Midhurst and Petworth Observer

Read More...

Protecting your Eyesight Against the Silent Advance of Glaucoma Pasadena Weekendr – Pasadena Now

August 12th, 2020 8:44 pm

Will I go blind? Its a frightening thought that most people have when they are first told they have glaucoma.

Patients are almost always concerned that they are going to lose their vision, says Andrew Iwach, M.D., executive director of the Glaucoma Center of San Francisco. The good news for the majority of patients is that we can maintain their vision with treatment.

The sneak thief of sight

Glaucoma, an eye disease that damages the optic nerve, is the leading cause of irreversible blindness. Currently, it affects more than three million people in the United States. The National Eye Institute projects this number will rise by 58% over the next decade to 4.2 million people.

The most common form of the disease is open-angle glaucoma, which affects 90% of patients and occurs when the eyes drainage canals become clogged over time, according to the Glaucoma Research Foundation.

Open-angle glaucoma has been called the sneak thief of sight because it strikes without symptoms. In fact, experts estimate that half of the patients who have glaucoma dont know it. As much as 40% of vision can be lost without a person noticing. And once that eyesight is lost, its permanently gone.

I didnt have any symptoms prior to diagnosis, says Richie Kahn, 34, who was diagnosed in March 2019. By then, glaucoma had already stolen part of my vision. I was surprised to learn that my brain was actually compensating for my vision loss by filling in the blanks.

Hope through treatment

Since glaucoma has no symptoms in its early stages and progresses slowly over many years, eye doctors emphasize the importance of regular eye exams to detect the disease before theres a significant loss of vision.

The target for glaucoma therapy is to lower intraocular pressure (IOP). High IOP causes damage to the optic nerve, which produces vision loss in the disease. Approaches to lowering IOP include a wide range of eye drop medications, laser treatments that are performed in a doctors office, and several types of incisional surgery.

Trinh Green, M.D., has lived with glaucoma for 24 years after being diagnosed at age 21. Like Richie, she had no symptoms of the disease, so news of her diagnosis came as a total surprise. Her advice to others is to remain calm and stay optimistic throughout their care and treatment.

I think its very important for people to stay calm after learning they have glaucoma, says Trinh. There are many more treatments available in the last few years. I also owe so much to Dr. Iwach. Hes a very calming presence. Whenever there was a setback and the disease progressed, he would tell me, I have a few more tricks up my sleeve.

The power of knowledge

In addition to early detection and treatment, Dr. Iwach emphasizes the importance of patients learning everything they can about glaucoma.

Getting the facts, including risk factors and treatment options, can empower patients to improve their outcomes and reduce their fears, he says.

Dr. Iwach encourages all his patients to read Understanding and Living with Glaucoma, published by the Glaucoma Research Foundation. The free booklet, updated and newly illustrated, offers a comprehensive introduction to glaucoma and guidance about how patients can work with their doctors to manage the disease.

Glaucoma patients like Richie found power in knowledge in their fight against glaucoma.

Everyones journey will be different and you have to be willing to advocate for yourself, says Richie. I learned a lot from the Glaucoma Research Foundation. Staying informed about my particular situation allows me to be an active member of my own care team, doing my part to preserve my vision.

A free copy of Understanding and Living with Glaucoma can be downloaded or ordered at http://www.glaucoma.org/booklet.

Post Views: 238

Read the rest here:
Protecting your Eyesight Against the Silent Advance of Glaucoma Pasadena Weekendr - Pasadena Now

Read More...

Page 455«..1020..454455456457..460470..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick